<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323920</url>
  </required_header>
  <id_info>
    <org_study_id>11-007</org_study_id>
    <nct_id>NCT01323920</nct_id>
  </id_info>
  <brief_title>Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors</brief_title>
  <official_title>Bortezomib-based Graft-Versus-Host-Disease Prophylaxis After Myeloablative Allogeneic Stem Cell Transplantation for Patients Lacking HLA-matched Related Donors: A Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a
      complication of transplantation where the donor graft attacks and damages some of your
      tissues. After stem cell transplant, all patients receive prophylactic medications against
      GVHD.

      In this research study, we are studying the safety and effectiveness of a bortezomib based
      GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call
      transplantation from a matched unrelated donor, mismatched related or unrelated donor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before your transplant you will receive conditioning therapy with fludarabine and busulfan
      given 7, 6, 5, and 4 days before your transplant. On day 0, you will receive selected blood
      cells taken from your sibling or unrelated donor.

      You will receive 3 drugs for your GVHD prophylaxis:

      Tacrolimus will be started 3 days before your transplant. It will be given intravenously and
      later by mouth. You will continue to take tacrolimus for 3 to 6 months after transplant.

      Methotrexate will be given intravenously 1, 3, 6 and 11 days after your transplant.

      Bortezomib will be given intravenously 1, 4, and 7 days after your transplant. On days 1, 4,
      7, 30 and 3, 6 and 12 months after your transplant you will have a physical exam, blood
      work, and be asked to complete a questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cumulative Incidence of Grade II-IV Acute GVHD by Day 100 After Stem Cell Infusion</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess Percentage Donor Engraftment by Day 30 Post Stem Cell Infusion</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess percentage donor engraftment by day 30 post stem cell infusion, defined as the first of 3 consecutive days tested of documented absolute netrophil count (ANC) &gt;/= 500 cells/u/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Assess Non-relapse Mortality, Progression-free and Overall Survival by 1 Year After Stem Cell Infusion</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine the Cumulative Incidence of Chronic GVHD Requiring Systemic Immune Suppression by 1 Year After Stem Cell Infusion</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Velcade/Tac/MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib, Tacrolimus, Methotrexate</intervention_name>
    <description>Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
    <arm_group_label>Velcade/Tac/MTX</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced and/or aggressive hematologic
             malignancy (including myelodysplastic syndrome) that is unlikely to be cured by
             alternative therapies

          -  HLA-Matched unrelated donor; or 1-locus HLA-mismatched related or unrelated donor

          -  ECOG performance status 0-2

          -  Adequate organ function

          -  Able to understand and willing to sign a written informed consent document

          -  Agrees to practice adequate contraception per study requirements

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Recipient of prior allogeneic or autologous stem cell transplantation

          -  Prior abdominal radiation therapy

          -  HIV-positive on combination antiretroviral therapy

          -  Seropositive for hepatitis B or C

          -  Allergies to bortezomib, boron, or mannitol

          -  Myocardial infarction within last 6 months, NYHA Class III or IV heart failure,
             uncontrolled angina, severe uncontrolled ventricular arrhythmias

          -  Uncontrolled bacterial, viral or fungal infections

          -  Seizures or history of seizures

          -  History of another non-hematologic malignancy unless disease-free for at least 5
             years

          -  Uncontrolled intercurrent illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Koreth, MBBS, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2011</firstreceived_date>
  <firstreceived_results_date>February 14, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>John Koreth, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Allogeneic Transplant</keyword>
  <keyword>Donors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Velcade/Tac/MTX</title>
          <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Velcade/Tac/MTX</title>
          <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Incidence of Grade II-IV Acute GVHD by Day 100 After Stem Cell Infusion</title>
        <time_frame>2 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Velcade/Tac/MTX</title>
            <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cumulative Incidence of Grade II-IV Acute GVHD by Day 100 After Stem Cell Infusion</title>
            <units>percent</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess Percentage Donor Engraftment by Day 30 Post Stem Cell Infusion</title>
        <description>To assess percentage donor engraftment by day 30 post stem cell infusion, defined as the first of 3 consecutive days tested of documented absolute netrophil count (ANC) &gt;/= 500 cells/u/L</description>
        <time_frame>2 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Velcade/Tac/MTX</title>
            <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>To Assess Percentage Donor Engraftment by Day 30 Post Stem Cell Infusion</title>
            <description>To assess percentage donor engraftment by day 30 post stem cell infusion, defined as the first of 3 consecutive days tested of documented absolute netrophil count (ANC) &gt;/= 500 cells/u/L</description>
            <units>percent</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess Non-relapse Mortality, Progression-free and Overall Survival by 1 Year After Stem Cell Infusion</title>
        <time_frame>2 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Velcade/Tac/MTX</title>
            <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>To Assess Non-relapse Mortality, Progression-free and Overall Survival by 1 Year After Stem Cell Infusion</title>
            <units>percent</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>non-relapse mortality</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>progression-free survival</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>overall survival</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Cumulative Incidence of Chronic GVHD Requiring Systemic Immune Suppression by 1 Year After Stem Cell Infusion</title>
        <time_frame>2 years</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Velcade/Tac/MTX</title>
            <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>To Determine the Cumulative Incidence of Chronic GVHD Requiring Systemic Immune Suppression by 1 Year After Stem Cell Infusion</title>
            <units>percent</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participating investigators will assess the occurrence of AEs and SAEs at all participant evaluation time points during the study.</time_frame>
      <desc>All AEs grades 3-5 and SAEs whether reported by the participant, discovered during questioning, directly observed, or detected by physical examination, laboratory test or other means, will be recorded in the participant’s medical record and on the appropriate study-specific case report forms.</desc>
      <group_list>
        <group group_id="E1">
          <title>Velcade/Tac/MTX</title>
          <description>Drug: Bortezomib, Tacrolimus, Methotrexate
Other Names:
Velcade
Bortezomib 1.3 mg/m^2 IV Tacrolimus 0.05 mg/kg PO bid Methotrexate 15 mg/m^2 IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>GVHD</sub_title>
                <description>2 participants passed away to Grade 5 GVHD</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HHV6/high LFTs</sub_title>
                <description>Grade 4 HHV-6 infection and elevated liver function tests</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>2 participants passed away to Grade 5 sepsis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Relapse</sub_title>
                <description>Grade 5 AML relapse complicated by respiratory failure, B.O.S, and pneumonia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Koreth</name_or_title>
      <organization>Dana Farber Cancer Institute</organization>
      <phone>617-632-2949</phone>
      <email>John_Koreth@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
